Halozyme Therapeutics HALO Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 82.8%-0.8pp | 83.6%-0.9pp | 84.5%+0.3pp | 84.2%+0.8pp | 83.4%-0.9pp | |
| Efficiency | ||||||
| Asset turnover | 0.6×0.0× | 0.6×0.0× | 0.6×0.0× | 0.6×0.0× | 0.5×0.0× | |
| Liquidity | ||||||
| Current ratio | 2.8×-1.9× | 4.7×+3.1× | 1.6×-6.8× | 8.4×0.0× | 8.4×+0.6× | |
| Leverage | ||||||
| Debt-to-equity | 9.9×-34.7× | 44.6×+41.5× | 3.1×-1.6× | 4.6×+1.4× | 3.2×-1.0× | |
| Per Share | ||||||
| Book value per share | $1.79+354% | $0.39-90.4% | $4.12+53.7% | $2.68-29.6% | $3.81+35.5% | |
| Valuation | ||||||
| Market capitalization | $7.66B-3.3% | $7.91B-7.7% | $8.58B+29.2% | $6.64B-15.7% | $7.88B+29.6% | |
| Price / sales | 5.1×-0.6× | 5.7×-1.2× | 6.9×+1.3× | 5.6×-1.6× | 7.3×+1.3× | |
| Price / book | 34.9×-127× | 162.1×+145× | 17×-2.9× | 20×+3.6× | 16.3×-0.4× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Halozyme Therapeutics's profit margins?
- Halozyme Therapeutics (HALO) runs a 82.8% gross margin and a 59.3% operating margin, with a 47.9% net margin.
- Where do Halozyme Therapeutics's ratios come from?
- Every ratio is computed from Halozyme Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
